Home LiteratureArticle Details
PMID: 15664922 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Infection and immunity ·Vol. 73 ·No. 2 ·2005-02-00 ·Pages 828-33

Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM

Abstract

To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.

MeSH Terms
Animals Anthrax/immunology,prevention & control Anthrax Vaccines/immunology Male Mice Microspheres Oligodeoxyribonucleotides/immunology Polyglactin 910 Time Factors
Chemicals
Anthrax Vaccines Oligodeoxyribonucleotides Polyglactin 910
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Xie Hang
Center for Biologics Evaluation Research, Food and Drug Administration, Bldg. 29A, Rm. 3D10, Bethesda, MD 20892, USA.
Gursel Ihsan
Ivins Bruce E
Singh Manmohan
O'Hagan Derek T
Ulmer Jeffrey B
Klinman Dennis M
References (40)
40 references, click to expand
  1. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.
    Vaccine. 2002 Jan 31;20(9-10):1412-20 PMID: 11818160
  2. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.
    Vaccine. 1999 Aug 6;17(23-24):3065-71 PMID: 10462241
  3. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios.
    Clin Exp Rheumatol. 2002 Mar-Apr;20(2):217-20 PMID: 12051402
  4. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.
    Vaccine. 2003 Jun 2;21(19-20):2461-7 PMID: 12744879
  5. Innate immunity and biodefence vaccines.
    Cell Microbiol. 2003 Nov;5(11):755-60 PMID: 14531891
  6. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles.
    Cell Immunol. 2003 Sep;225(1):12-20 PMID: 14643300
  7. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.
    Vaccine. 2004 Jan 2;22(3-4):422-30 PMID: 14670324
  8. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.
    Nat Med. 2004 Feb;10(2):187-92 PMID: 14745443
  9. US soldiers refuse to fall in line with anthrax vaccination scheme.
    Nat Med. 2004 Feb;10(2):112 PMID: 14760404
  10. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.
    Microb Pathog. 1988 Aug;5(2):127-39 PMID: 3148815
  11. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen.
    Infect Immun. 1990 Feb;58(2):303-8 PMID: 2105269
  12. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.
    J Infect Dis. 1992 Jan;165(1):34-45 PMID: 1727896
  13. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.
    Infect Immun. 1992 Feb;60(2):662-8 PMID: 1730501
  14. CpG motifs in bacterial DNA trigger direct B-cell activation.
    Nature. 1995 Apr 6;374(6522):546-9 PMID: 7700380
  15. Molecular pathogenesis of Bacillus anthracis infection.
    Microbes Infect. 1999 Feb;1(2):131-9 PMID: 10594977
  16. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.
    Vaccine. 2000 Mar 17;18(18):1920-4 PMID: 10699341
  17. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells.
    Gene Ther. 2000 Dec;7(24):2105-12 PMID: 11223992
  18. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Microbiology. 2001 Jun;147(Pt 6):1677-85 PMID: 11390699
  19. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.
    Pharm Res. 2001 May;18(5):709-12 PMID: 11465430
  20. Microparticles for intranasal immunization.
    Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):127-41 PMID: 11516784
  21. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.
    J Virol. 2001 Oct;75(19):9037-43 PMID: 11533167
  22. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.
    J Immunol. 2001 Sep 15;167(6):3324-8 PMID: 11544321
  23. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA.
    Pharm Res. 2001 Oct;18(10):1476-9 PMID: 11697476
  24. Bioterrorism: a clear and present danger.
    Nat Med. 2001 Dec;7(12):1271-3 PMID: 11726956
  25. Anthrax vaccine: short-term safety experience in humans.
    Vaccine. 2001 Dec 12;20(5-6):972-8 PMID: 11738765
  26. Immunotherapeutic uses of CpG oligodeoxynucleotides.
    Nat Rev Immunol. 2004 Apr;4(4):249-58 PMID: 15057783
  27. Charged polylactide co-glycolide microparticles as antigen delivery systems.
    Expert Opin Biol Ther. 2004 Apr;4(4):483-91 PMID: 15102598
  28. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
    Vaccine. 2004 Jul 29;22(21-22):2881-6 PMID: 15246624
  29. Recent advances in the development of an improved, human anthrax vaccine.
    Eur J Epidemiol. 1988 Mar;4(1):12-9 PMID: 3128450
  30. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.
    J Biol Chem. 1995 Nov 17;270(46):27920-31 PMID: 7499267
  31. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha.
    Cell Immunol. 1996 Jan 10;167(1):72-8 PMID: 8548847
  32. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 PMID: 8610135
  33. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    J Immunol. 1996 Sep 1;157(5):1840-5 PMID: 8757300
  34. Order-restricted tests for stratified comparisons of binomial proportions.
    Biometrics. 1996 Sep;52(3):1103-11 PMID: 8805770
  35. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice.
    Vaccine. 1997 Apr;15(5):475-81 PMID: 9160514
  36. Anthrax pathogenesis and host response.
    Curr Top Microbiol Immunol. 1998;225:13-35 PMID: 9386326
  37. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    J Immunol. 1998 Jan 15;160(2):870-6 PMID: 9551923
  38. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.
    Vaccine. 1998 Jul;16(11-12):1141-8 PMID: 9682372
  39. CpG motifs as immune adjuvants.
    Vaccine. 1999 Jan;17(1):19-25 PMID: 10078603
  40. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
    J Immunol. 2002 Feb 15;168(4):1659-63 PMID: 11823494
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
DOI
10.1128/IAI.73.2.828-833.2005
Published
2005-02-00
Pages
828-33
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC547063
Subset
IM
External Links
PubMed source DOI: 10.1128/IAI.73.2.828-833.2005 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2